- Focal Segmental Glomerulosclerosis (FSGS), a severe form of nephrotic syndrome marked by scarring in the kidney’s filtering units, is driving significant focus in the global nephrology therapeutics space due to its progressive nature and potential to cause end-stage renal disease
- The growing prevalence of primary and secondary FSGS, increasing awareness about chronic kidney conditions, and the surge in clinical trials exploring novel treatment modalities, including biologics and immunosuppressants, are key factors fueling market growth
- North America dominated the focal segmental glomerulosclerosis market with the largest revenue share of 47.4% in 2024, driven by the presence of advanced healthcare infrastructure, robust research funding, and rising incidence of kidney diseases, particularly in the U.S. where early diagnosis and access to innovative therapies are accelerating treatment adoption
- Asia-Pacific is expected to witness the fastest growth during the forecast period due to improving healthcare access, growing awareness of nephrology disorders, and increased government initiatives to combat chronic kidney diseases
- Primary segment dominated the focal segmental glomerulosclerosis market with a market share of 70.5% in 2024, driven by its higher prevalence and the urgent need for early and targeted therapeutic interventions due to its progressive nature
